cis-3-Aminotetrahydro-2H-pyran-4-ol hydrochloride | 1657033-39-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: cis-3-Aminotetrahydro-2H-pyran-4-ol hydrochloride
• 英文别名: (3R,4S)-3-aminooxan-4-ol;hydrochloride
• CAS: 1657033-39-0
• 化学式: C5H12ClNO2
• 分子量: 153.61
• InChiKey: SFJKFFBPVORSEB-JBUOLDKXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.48
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55.5
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10087150B2

  公开（公告）日：2018-10-02

  The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

  本发明提供了一种具有胆碱能毒蕈碱 M1 受体正异位调节剂活性的化合物，该化合物可用作阿尔茨海默病、精神分裂症、疼痛、睡眠障碍、帕金森病痴呆、路易体痴呆等的预防或治疗药物。本发明涉及一种由式（I）代表的化合物或其盐： 其中各符号如所附说明书中定义。
• 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10323027B2

  公开（公告）日：2019-06-18

  The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

  本发明提供了一种具有胆碱能毒蕈碱M1受体正异位调节剂活性的化合物，它可作为阿尔茨海默病、精神分裂症、疼痛、睡眠障碍、帕金森病痴呆、路易体痴呆等的预防或治疗药物。本发明涉及一种由式（I）代表的化合物或其盐：其中各符号如所附说明书中定义。
• Muscarinic M1 receptor positive allosteric modulators
  申请人：SUVEN LIFE SCIENCES LIMITED

  公开号：US11040026B2

  公开（公告）日：2021-06-22

  The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt(s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).

  本发明涉及作为毒蕈碱 M1 受体正异位调节剂（M1 PAMs）的式（I）化合物或其同位素形式、立体异构体、同系物或药学上可接受的盐。本发明描述了式 (I) 化合物的制备、药物组合物和用途。
• 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3313836B1

  公开（公告）日：2020-11-11
• EP3507289A1
  申请人：——

  公开号：EP3507289A1

  公开（公告）日：2019-07-10